Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,573 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma
Interventions
oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
British Columbia Cancer Agency
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Stanford, California
Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell
Interventions
GLPG5101
Genetic
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
imetelstat sodium, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
Conditions
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Duarte, California
Completed No phase listed Observational Accepts healthy volunteers

Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

NCT01623856
Conditions
Childhood Burkitt Lymphoma, Childhood Lymphoblastic Lymphoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
483 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Monrovia, California
Active, not recruiting Phase 1Phase 2 Interventional

Copanlisib Plus Venetoclax in R/R DLBCL

NCT04572763
Conditions
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Copanlisib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • St Louis, Missouri
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Tafasitamab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoma, Non-Hodgkin, HIV Infections
Interventions
Mitoguazone
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Antonio, Texas
Completed No phase listed Observational Accepts healthy volunteers

Severe Asthma Research Program

NCT01606826
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years and older
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
MEDI-551 2 mg/kg, Rituximab, ICE, DHAP, Autologous Stem Cell Transplant (ASCT), MEDI-551 4 mg/kg
Drug · Procedure
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Burbank, California • Palm Springs, California + 25 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Ofatumumab, Carboplatin, Etoposide, CT Scan, PET Scan, Stem Cell Transplant (STC)
Drug · Procedure · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
Interventions
Idecabtagene vicleucel, Lisocabtagene maraleucel
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
50 participants
Timeline
2023 – 2038
U.S. locations
4
States / cities
Portland, Oregon • Dallas, Texas • Salt Lake City, Utah + 1 more
Conditions
Mantle Cell Lymphoma, Untreated
Interventions
Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mantle Cell Lymphoma
Interventions
Leuprolide acetate depot (LAD) 11.25 mg 3 Month, Matched placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Durham, North Carolina + 1 more
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
arsenic trioxide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma
Interventions
ONC-PluReceptor NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Interventions
denileukin diftitox, dexamethasone
Biological · Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
11
States / cities
Miami, Florida • Chicago, Illinois • New Orleans, Louisiana + 8 more
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
penclomedine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Shwachman-Diamond Syndrome, SDS, IBMF, Congenital Neutropenia, Heme Malignancy, Shwachman Syndrome, Inherited Bone Marrow Failure, Exocrine Pancreatic Insufficiency, WHIM, ELANE, SBDS Gene Mutation, EFL1 Gene Mutation, DNAJC21 Gene Mutation, SRP54 Gene Mutation, Inherited Cancer Syndrome, Inherited Cancer-Predisposing Syndrome, Neutropenia, Severe Chronic, Neutropenia Other, Neutropenia Chronic Benign, Ribosome Alteration, Ribosomopathy, Immune Deficiency, Inherited BMF Syndrome, Inherited Immunodeficiency Diseases, Cognitive Delay, Mild, Myelodysplastic Syndromes, Pancytopenia
Interventions
Not listed
Lead sponsor
Shwachman-Diamond Syndrome Alliance Inc
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2088
U.S. locations
1
States / cities
Woburn, Massachusetts
Conditions
Lymphoma
Interventions
aldesleukin, rituximab
Biological
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Rochester, New York
Conditions
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Conditions
Marginal Zone Lymphoma, MZL
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Westbury, New York • Charlotte, North Carolina